Marko Boc (Author), Tanja Mesti (Author), Martina Reberšek (Author)

Abstract

Klinični primer bolnika z razsejanim ploščatoceličnim karcinomom požiralnika

Keywords

rak požiralnika;ploščatocelični rak;radiokemoterapija;rak prebavil;

Data

Language: Slovenian
Year of publishing:
Typology: 1.09 - Published Professional Conference Contribution
Organization: OI - Institute of Oncology
UDC: 616.3-006
COBISS: 1809787 Link will open in a new window
ISSN: 1408-1741
Parent publication: Šola: tumorji prebavil II, Ljubljana, 15. 11. 2013
Views: 2116
Downloads: 635
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: English
Secondary title: [ǂA ǂclinical case of a patient with metastatic squamous cells carcinoma of the oesophagus]
Secondary abstract: The incidence of oesophageal cancer has not changed in the last years, neither in the world nor in Slovenia. According to the 2012 Cancer Registry of Slovenia, a total of 87 patients were diagnosed with oesophageal cancer in 2009, of which 74 were males and 13 were females. The most common histological type was squamous cell carcinoma; in 2009, there were 60 such patients, while adenocarcinoma, which is the second most common type, was found in 19 patients. Patients with oesophageal cancer have a poor prognosis. A half of these patients have advanced disease already at diagnosis. Median survival with advanced disease is eight to ten months, while 5-year survival is merely 5-17%. When the disease is operable, patients are treated surgically, and if the disease is limited locoregionally, the patients are treated with pre-operative chemoradiotherapy and surgery. However, despite such primary treatment, the disease recurs in approximately 65% of patients in the first five years, either in a form of metastases or as a local recurrence (2, 3, 4, 5, 6). In this article, we present a patient with squamous cell carcinoma of the middle third of the oesophagus which has started to spread to the upper and lower thirds six months after primary treatment and effective first-line systemic treatment.
URN: URN:NBN:SI
Pages: str. 63-64, 76
Volume: ǂLetn. ǂ18
Issue: ǂšt. ǂ1
Chronology: jun. 2014
ID: 10956476